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The success of antibody-based theranostics depends on
the identification of tumor specific biomarkers and the
development of corresponding antibodies with high-affi-
nity and specificity. Tumor endothelial marker-1
(TEM1) is highly expressed in tumor vasculature of
multiple cancers but not in normal organs. The expres-
sion of TEM1 was first evaluated and confirmed by
immunohistochemistry from 53 cases of metastatic ser-
ous ovarian cancer at HUP. TEM1 positive tumor
stroma was observed in >95% of the cases studied.
Hence, developing sensitive and effective theranostic
agents against TEM1 are of utmost significance in
improving diagnosis and treatment of ovarian cancer.
Our goals are: 1) engineer TEM1-specific antibodies; 2)
evaluate these engineered antibodies in imaging and
immunotherapies in preclinical models. To generate
TEM1-targeting agents, we designed a panel of multiva-
lent fusion proteins from scFv78, a previously isolated
single chain variable fragment specifically recognizing
the extracellular domain of TEM1. scFv78 was fused
with different huIgG1 Fc region (CH2-, CH3-, or hinge).
Proteins were expressed in 293F cells and purified by
affinity chromatography. All scFv78 variants exhibited
comparable thermo and serum stability in vitro. Among
them, the scFv78-Fc fusion (78Fc) has the highest affi-
nity to TEM1 (Kd = 0.15nM, 15X higher than scFv78).
Pharmacokinetics (PK) and biodistribution of the pro-
tein panel were evaluated in naïve and TEM1+ tumor
bearing animals. 78Fc has a t1/2 of 5.1hr, which is suita-
ble for in vivo therapeutic and imaging applications.
Therefore, 78Fc was further developed as imaging tool
and antibody-drug conjugate (ADC) based on its favor-
able affinity, stability, half-life and PK profile. In pilot
studies with preclinical animal models of tumor vascula-
ture, fluorophore- and [124-I]-labeled 78Fc demon-
strated specific enrichment in TEM1+ grafts, but not in
control tumor or other organs, by both optical and
immunoPET imaging. In addition, 78Fc-MMAE conju-
gate exerted specific killing of TEM1+ cells. In sum-
mary, we have developed a panel of innovative
theranostics agents targeting TEM1 on the vasculature
of ovarian cancer and several other solid tumors. Our
long term goal is to translate such combined approach
into the clinic: Using TEM1-antibody as imaging tools
to select, and monitor patients for TEM1-antibody
based targeted therapies.
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